Skip to Main Content
Table 3

eGFR decline according to quartiles of increasing baseline sTNFR1 (pg/mL) stratified by baseline diabetes and adjusting for known risk factors

sTNFR1Participants (n)Model 1
Model 2
Model 3
Model 4
β95% CIP valueβ95% CIP valueβ95% CIP valueβ95% CIP value
No diabetes (n = 238)              
 Q1 73 Reference   Reference   Reference   Reference   
 Q2 69 1.04 −0.73 to 2.82 0.25 1.02 −0.74 to 2.79 0.25 1.07 −0.72 to 2.85 0.24 1.00 −0.78 to 2.72 0.27 
 Q3 56 1.34 −0.64 to 3.31 0.18 1.22 −0.70 to 3.14 0.21 1.36 −0.59 to 3.30 0.17 1.16 −0.80 to 3.13 0.24 
 Q4 40 −1.22 −3.58 to 1.14 0.31 −1.24 −3.59 to 1.11 0.30 −1.19 −3.57 to 1.18 0.32 −1.34 −3.72 to 1.04 0.27 
sTNFR1* — −0.34 −2.63 to 1.95 0.77 −0.35 −2.61 to 1.91 0.76 −0.27 −2.55 to 2.00 0.81 −0.49 −2.79 to 1.80 0.68 
Diabetes (n = 171)              
 Q1 30 Reference   Reference   Reference   Reference   
 Q2 39 −0.12 −2.98 to 2.72 0.93 −0.27 −3.13 to 2.59 0.85 −0.11 −2.95 to 2.74 0.94 −0.16 −3.00 to 2.68 0.91 
 Q3 43 −1.25 −4.04 to 1.54 0.38 −1.39 −4.17 to 1.38 0.32 −1.42 −4.19 to 1.36 0.32 −1.31 −4.08 to 1.46 0.35 
 Q4 59 −4.38 −7.50 to −1.25 0.006 −4.36 −7.50 to −1.22 0.007 −4.41 −7.54 to −1.28 0.006 −4.17 −7.32 to −1.00 0.01 
sTNFR1* — −5.95 −8.90 to −3.01 <0.001 −5.70 −8.66 to −2.74 <0.001 −5.70 −8.64 to −2.75 <0.001 −5.53 −8.52 to −2.56 <0.001 
sTNFR1Participants (n)Model 1
Model 2
Model 3
Model 4
β95% CIP valueβ95% CIP valueβ95% CIP valueβ95% CIP value
No diabetes (n = 238)              
 Q1 73 Reference   Reference   Reference   Reference   
 Q2 69 1.04 −0.73 to 2.82 0.25 1.02 −0.74 to 2.79 0.25 1.07 −0.72 to 2.85 0.24 1.00 −0.78 to 2.72 0.27 
 Q3 56 1.34 −0.64 to 3.31 0.18 1.22 −0.70 to 3.14 0.21 1.36 −0.59 to 3.30 0.17 1.16 −0.80 to 3.13 0.24 
 Q4 40 −1.22 −3.58 to 1.14 0.31 −1.24 −3.59 to 1.11 0.30 −1.19 −3.57 to 1.18 0.32 −1.34 −3.72 to 1.04 0.27 
sTNFR1* — −0.34 −2.63 to 1.95 0.77 −0.35 −2.61 to 1.91 0.76 −0.27 −2.55 to 2.00 0.81 −0.49 −2.79 to 1.80 0.68 
Diabetes (n = 171)              
 Q1 30 Reference   Reference   Reference   Reference   
 Q2 39 −0.12 −2.98 to 2.72 0.93 −0.27 −3.13 to 2.59 0.85 −0.11 −2.95 to 2.74 0.94 −0.16 −3.00 to 2.68 0.91 
 Q3 43 −1.25 −4.04 to 1.54 0.38 −1.39 −4.17 to 1.38 0.32 −1.42 −4.19 to 1.36 0.32 −1.31 −4.08 to 1.46 0.35 
 Q4 59 −4.38 −7.50 to −1.25 0.006 −4.36 −7.50 to −1.22 0.007 −4.41 −7.54 to −1.28 0.006 −4.17 −7.32 to −1.00 0.01 
sTNFR1* — −5.95 −8.90 to −3.01 <0.001 −5.70 −8.66 to −2.74 <0.001 −5.70 −8.64 to −2.75 <0.001 −5.53 −8.52 to −2.56 <0.001 

Data are milliliters per minute per 1.73 m2 per year unless otherwise indicated. Multivariate models are based on all participants without missing data (n = 409). All models were adjusted for baseline age, sex, CKD-EPI eGFR, uACR, history of ischemic heart disease or myocardial infarction, smoking (never, former, and current). Model 1 was also adjusted for waist-to-hip ratio, model 2 was also adjusted for the natural logarithm of HbA1c (mmol/mol), model 3 was also adjusted for hypertension, and model 4 was also adjusted for CRP (natural logarithm). CKD-EPI eGFR was calculated using the CKD-EPI eGFR equation based on serum creatinine without correction for African American ethnicity.

*sTNFR1 was transformed using the natural logarithm.

Close Modal

or Create an Account

Close Modal
Close Modal